Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 7 7 IN PLASTIC CONTAINER versus NORMOSOL R IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 7 7 IN PLASTIC CONTAINER versus NORMOSOL R IN PLASTIC CONTAINER.
DEXTROSE 7.7% IN PLASTIC CONTAINER vs NORMOSOL-R IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose is a simple sugar that provides a source of calories and fluid for intravenous administration. It increases blood glucose levels, enhancing cellular metabolism and energy production via the glycolytic pathway and subsequent oxidative phosphorylation.
Normosol-R is an isotonic crystalloid solution that replaces extracellular fluid volume and electrolytes. It provides sodium, chloride, potassium, magnesium, acetate, and gluconate to maintain acid-base balance and osmotic equilibrium. Acetate and gluconate are metabolized to bicarbonate, providing an alkalinizing effect.
Intravenous infusion. Typical adult dose is 500-1000 mL of 7.7% dextrose solution infused at a rate of 100-200 mL/hour, titrated to clinical response and serum glucose levels.
Intravenous infusion; dose determined by electrolyte and fluid requirements; typical adult dose: 250-1000 mL/hour, not to exceed 30 mL/kg/day.
None Documented
None Documented
30-60 minutes for blood glucose to return to baseline after infusion cessation; clinical context: rapid metabolism via glycolysis.
Not applicable as a drug; the half-life of infused crystalloid components is distribution-dependent. Sodium and chloride have a terminal half-life of approximately 2-4 hours in healthy adults, reflecting renal clearance. Clinical context: Half-life prolonged in renal impairment.
Renal: 100% as CO2 and water; no unchanged dextrose excreted in urine under normal conditions.
Renal excretion of electrolytes and water; no hepatic metabolism. >95% of administered water and electrolytes are excreted renally, with small amounts lost via feces (<2%) and insensible losses.
Category C
Category C
Intravenous Fluid
Intravenous Fluid/Electrolyte Solution